Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,065.00-1.18%ETH$2,470.33+0.03%GOLD$4,386.00-0.48%OIL$99.65-2.76%
Smart Investors Daily
PC

NASDAQ · PCVX

Vaxcyte, Inc. Common Stock

Healthcare · Biotechnology

$58.90

Down-$0.61 (-1.03%)

Updated Sep 11, 2026, 10:06 AM

SID Score

6.3/10

Composite research score

Smart Money

58/100

Neutral

Market cap
5.84B
P/E ratio
-9.24
Dividend yield
0.00%
52-week range
$30.81 – $65.00
Volume
1.16M
Avg. volume
1.73M

Price performance

PCVX price history

1M range · 20 trading sessions · Daily adjusted prices

PCVX closed at $58.90 after 20 trading sessions, up 0.07% for the selected period.

Last close
$58.90
Period change
+0.07%
Period low
$58.07
Period high
$63.30
Daily close
View OHLC price history
PCVX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$59.19$60.13$58.555$58.901.16M
Sep 9, 2026$59.99$60.33$59.045$59.511.2M
Sep 8, 2026$60.25$61.03$59.22$60.361.02M
Sep 4, 2026$59.73$61.78$59.645$61.16986.71K
Sep 3, 2026$61.73$62.14$59.85$61.17736.47K
Sep 2, 2026$61.63$62.90$60.82$61.581.02M
Sep 1, 2026$60.29$62.14$60.06$60.811.44M
Aug 31, 2026$59.10$61.61$58.51$60.741.75M
Aug 28, 2026$61.06$62.375$59.485$59.835760.16K
Aug 27, 2026$60.51$61.60$59.93$61.155611.75K
Aug 26, 2026$61.035$61.645$60.32$61.09891.7K
Aug 25, 2026$62.22$63.92$60.96$61.091.22M
Aug 24, 2026$62.30$63.05$61.23$61.87662.14K
Aug 21, 2026$61.60$63.98$61.60$62.621.14M
Aug 20, 2026$62.23$62.91$60.80$61.34726.44K
Aug 19, 2026$61.56$63.83$60.945$63.301.44M
Aug 18, 2026$59.97$60.86$59.50$59.79705.94K
Aug 17, 2026$58.03$60.29$57.3432$60.22712.9K
Aug 14, 2026$58.11$58.745$57.3001$58.07656.56K
Aug 13, 2026$60.00$60.45$58.72$58.86839.08K

Latest PCVX news

The latest Smart Investors Daily articles mentioning PCVX.

Stock researchCompany · Overview

PCVX research

Overview

Company profile and research snapshot.

Company profile

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$77.00
Implied upside
—
Analysts
—
PCVX recent ratings
DateFirmRatingTarget
Feb 26, 2026BTIGBuy—
Feb 2, 2026GuggenheimBuy—
Jan 7, 2026NeedhamBuy—
Nov 10, 2025BTIGBuy—
Sep 12, 2025Goldman SachsNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer David McAvoy, J.D., Former Teva Chief Legal Officer, Joins Vaxcyte as Chief Legal Officer Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Pivotal Trial Expected by End of October 2026

Yahoo · Aug 27, 2026

Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference, September 8-10, 2026: Fireside chat will take place on Tuesday, September 8 at 3:00 p.m. ET / 12:00 p.m. PT.Cantor Global Healthcare Conference, September 9-11, 2026: Fireside chat

Benzinga · Aug 5, 2026

Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensus estimate of $(2.22) by 11.26 percent. This is a 61.48 percent decrease over losses of $(1.22) per share from the same

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By